It's not just GSK, many large pharma are struggling to replace patent protected drugs. This is where Biota are at an advantage, with a phase II and Phase III completed, unlicensed drug looking for a partner.
I'm not worried about Relenza sales... the stockpiling market is proven and it's only a matter of time before rotation allows for more Relenza, LANI and others to gain their rightful place.
more confusion over vaccine vs antiviral, page-13
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)